POULIMENEAS, Dimitrios, Markela KONIORDOU, Dimitra KOUSI, Christina MERAKOU, Ioannis KOPSIDAS, Grammatiki Christina TSOPELA, Christos D ARGYROPOULOS, Sophia C THEMISTOCLEOUS, George SHIAMAKKIDES, Marinos CONSTANTINOU, Alexandra ALEXANDROU, Evgenia NOULA, Andria NEARCHOU, Jon SALMANTON-GARCÍA, Fiona A STEWART, Sarah HERINGER, Kerstin ALBUS, Elena ÁLVAREZ-BARCO, Alan MACKEN, Romina Di MARZO, Catarina LUIS, Paula VALLE-SIMÓN, Helena H ASKLING, Margot HELLEMANS, Orly SPIVAK, Ruth Joanna DAVIS, Anna Maria AZZINI, Imre BARTA, Lenka SOUČKOVÁ, Ligita JANCORIENE, Murat AKOVA, Patrick W G MALLON, Ole F OLESEN, Jesus FRIAS-INIESTA, Pierre van DAMME, Krisztina TÓTH, Miriam COHEN-KANDLI, Rebecca Jane COX, Petr HUSA, Pontus NAUCLÉR, Laura MARQUES, Jordi OCHANDO, Evelina TACCONELLI, Markus ZEITLINGER, Oliver A CORNELY, Zoi Dorothea PANA a Theoklis E ZAOUTIS. The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium. Vaccines. Basel: MDPI, 2023, roč. 11, č. 12, s. 1784-1795. ISSN 2076-393X. Dostupné z: https://dx.doi.org/10.3390/vaccines11121784.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium
Autoři POULIMENEAS, Dimitrios, Markela KONIORDOU, Dimitra KOUSI, Christina MERAKOU, Ioannis KOPSIDAS, Grammatiki Christina TSOPELA, Christos D ARGYROPOULOS, Sophia C THEMISTOCLEOUS, George SHIAMAKKIDES, Marinos CONSTANTINOU, Alexandra ALEXANDROU, Evgenia NOULA, Andria NEARCHOU, Jon SALMANTON-GARCÍA, Fiona A STEWART, Sarah HERINGER, Kerstin ALBUS, Elena ÁLVAREZ-BARCO, Alan MACKEN, Romina Di MARZO, Catarina LUIS, Paula VALLE-SIMÓN, Helena H ASKLING, Margot HELLEMANS, Orly SPIVAK, Ruth Joanna DAVIS, Anna Maria AZZINI, Imre BARTA, Lenka SOUČKOVÁ (203 Česká republika, domácí), Ligita JANCORIENE, Murat AKOVA, Patrick W G MALLON, Ole F OLESEN, Jesus FRIAS-INIESTA, Pierre van DAMME, Krisztina TÓTH, Miriam COHEN-KANDLI, Rebecca Jane COX, Petr HUSA (203 Česká republika, domácí), Pontus NAUCLÉR, Laura MARQUES, Jordi OCHANDO, Evelina TACCONELLI, Markus ZEITLINGER, Oliver A CORNELY, Zoi Dorothea PANA a Theoklis E ZAOUTIS.
Vydání Vaccines, Basel, MDPI, 2023, 2076-393X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30303 Infectious Diseases
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 7.800 v roce 2022
Kód RIV RIV/00216224:14110/23:00132500
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/vaccines11121784
UT WoS 001131427300001
Klíčová slova anglicky barriers; COVID-19; Europe; pandemic preparedness; SARS-CoV-2; vaccinations; vaccine education; vaccine trials
Štítky 14110214, 14110516, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 27. 2. 2024 14:13.
Anotace
Underserved and hard-to-reach population groups are under-represented in vaccine trials. Thus, we aimed to identify the challenges of vaccine trial participation of these groups in member countries of the VACCELERATE network. Seventeen National Coordinators (NC), each representing their respective country (15 European countries, Israel, and Turkey), completed an online survey. From 15 eligible groups, those that were more frequently declared underserved/hard-to-reach in vaccine research were ethnic minorities (76.5%), persons experiencing homelessness (70.6%), illegal workers and refugees (64.7%, each). When prioritization for education on vaccine trials was considered, ethnic groups, migrants, and immigrants (5/17, 29.4%) were the groups most frequently identified by the NC as top targets. The most prominent barriers in vaccine trial participation affecting all groups were low levels of health literacy, reluctance to participate in trials due to engagement level, and low levels of trust in vaccines/vaccinations. This study highlighted population groups considered underserved/hard-to-reach in countries contained within the European region, and the respective barriers these groups face when participating in clinical studies. Our findings aid with the design of tailored interventions (within—and across—countries of the European region) and with the development of strategies to overcome major barriers in phase 2 and phase 3 vaccine trial participation.
Návaznosti
90249, velká výzkumná infrastrukturaNázev: CZECRIN IV
VytisknoutZobrazeno: 30. 4. 2024 16:17